on BIOSYNEX (EPA:ALBIO)
BIOSYNEX successfully completes its capital increase
BIOSYNEX announces the success of its capital increase with preferential subscription rights, raising €7.99 million. This operation made it possible to issue 7,987,161 new shares at a unit price of €1.00, representing a discount of 48% compared to the VWAP. Shareholders subscribed massively, recording an oversubscription rate of 107%.
The capital increase allows BIOSYNEX to strengthen its balance sheet, securing its cash flow for more than twelve months. The settlement-delivery of the new shares is scheduled for February 14, 2025 on Euronext Growth Paris.
The dilution of existing shareholders is significant, with their stake dropping from 1% to 0.57%. The transaction includes irrevocable commitments from the main shareholder and new investors, respecting commitments to creditors.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all BIOSYNEX news